Treatment Outcomes of Scleroderma With Janus Kinase Inhibitors: A Systematic Review

Abstract

Keywords

diffuse cutaneous systemic sclerosis Janus Kinase inhibitors localized cutaneous systemic sclerosis morphea scleroderma systemic sclerosis systematic review therapeutic treatment

Get full access to this article

View all access options for this article.

References

Odonwodo

Badri

Hariz

. Scleroderma. In: StatPearls. StatPearls Publishing; 2023.

. Scleroderma in children and adolescents: localized scleroderma and systemic sclerosis. Pediatr Clin North Am. 2018;65(4):757-781. doi:10.1016/j.pcl.2018.04.002

Wang

Bhattacharyya

Marangoni

, et al The JAK/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib. J Scleroderma Relat Disord. 2020;5(1):40-50. doi:10.1177/2397198319865367

Karatas

Celik

, et al Tofacitinib and metformin reduce the dermal thickness and fibrosis in mouse model of systemic sclerosis. Sci Rep. 2022;12(1):2553. doi:10.1038/s41598-022-06581-1

Schwartz

Kanno

Villarino

Ward

Gadina

O’Shea

. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;17(1):78. doi:10.1038/nrd.2017.267

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB

0.06 MB

0.02 MB

0.42 MB